公开(公告)号：US20230065034A1

公开(公告)日：2023-03-02

申请号：US17782615

申请日：2020-12-01

申请人： Neurocrine Biosciences, Inc.

发明人： Neil J. ASHWEEK ,  John P. WILLIAMS ,  Lev Alexander ZEGELMAN ,  Christina Marie COSTA ,  Scott STIRN ,  Shawn BRANUM ,  Jackie LE ,  John Lloyd TUCKER ,  Brian M. COCHRAN ,  David KUCERA ,  Donald HETTINGER ,  Max A. MELLMER

IPC分类号： C07D487/04 ,  C07D233/20 ,  C07D231/54 ,  G01N33/74 ,  A61P5/00

摘要： Compounds are provided herein that antagonize corticotropin-releasing factor (CRF) receptors, in particular CRF receptor 1 (CRF1), as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).

公开(公告)号：US20220363680A1

公开(公告)日：2022-11-17

申请号：US17641705

申请日：2020-09-11

申请人： Neurocrine Biosciences, Inc.

发明人： John TUCKER ,  David KUCERA ,  Donald HETTINGER ,  Brian M. COCHRAN ,  Shawn BRANUM ,  Jackie LE ,  Kevin MCGEE

IPC分类号： C07D471/04 ,  A61K47/12 ,  A61K47/36

摘要： The present application relates to processes for making (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b -hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl (S)-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), which is an inhibitor of vesicular monoamine transporter 2 (VMAT2) useful in the treatment of hyperkinetic movement disorders such as tardive dyskinesia (TD).